Companies › Calla Lily Clinical Care
1 active drug program in 22 registered trials: 11 Phase 4, 4 Phase 3, 4 Phase 2, 3 Phase 1; Genitourinary, Infectious disease, Metabolic and endocrine, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Progesterone Progesterone receptor agonist | PGR | Phase 1 | Luteal Phase Insuffiency; Luteal Support; Smoking; Pregnancy Related … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06102863 | Progesterone | Phase 2 | Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I | Oncology | Aug 2025 |
| NCT05969795 | Progesterone | Phase 1 | Pregnancy Related | Genitourinary | Apr 2026 |
| NCT06875752 | Progesterone | Phase 4 | Luteal Support | Other | Dec 2026 |
| NCT06875752 | Progesterone | Phase 4 | Luteal Support | Other | Dec 2026 |
| NCT07136922 | Progesterone | Phase 1 | Luteal Phase Insuffiency | Other | Dec 2026 |
| NCT07136922 | Progesterone | Phase 1 | Luteal Phase Insuffiency | Other | Dec 2026 |
| NCT06807580 | Progesterone | Phase 2 | Transgender Women | Other | Feb 2027 |
| NCT06530459 | Progesterone | Phase 2 | Arthralgia | Genitourinary | Apr 2027 |
| NCT04783857 | Progesterone | Phase 4 | Smoking | Other | Jun 2027 |
| NCT05899010 | Progesterone | Phase 3 | Infertility | Genitourinary | Jun 2027 |
| NCT05899010 | Progesterone | Phase 3 | Infertility | Genitourinary | Jun 2027 |
| NCT05080569 | Progesterone | Phase 4 | Pregnancy Related | Genitourinary | Jul 2027 |
| NCT06856174 | Progesterone | Phase 4 | HIV Infection | Infectious disease | Sep 2027 |
| NCT05586724 | Progesterone | Phase 3 | Menopausal Symptoms | Genitourinary | Dec 2027 |
| NCT06610305 | Progesterone | Phase 4 | Major Depressive Disorder | Psychiatry | Jun 2028 |
| NCT06834594 | Progesterone | Phase 4 | Turner Syndrome | Metabolic and endocrine | Jul 2028 |
| NCT06834594 | Progesterone | Phase 4 | Turner Syndrome | Metabolic and endocrine | Jul 2028 |
| NCT07448597 | Progesterone | Phase 4 | Preeclampsia | Other | Aug 2028 |
| NCT05787509 | Progesterone | Phase 4 | Preterm Birth | Other | Apr 2029 |
| NCT07508657 | Progesterone | Phase 4 | Infertility | Genitourinary | Jun 2029 |
| NCT07436793 | Progesterone | Phase 2 | Endometrial Endometrioid Adenocarcinoma | Oncology | Jun 2030 |
| NCT06851754 | Progesterone | Phase 3 | Premature Ovarian Insufficiency | Metabolic and endocrine | Dec 2031 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.